ahlam1399
03-21-2016, 02:44 PM
BRIEF-Bellerophon Therapeutics Inc receives final FDA confirmation to initiate Phase 3 studies using next generation i**pulse device
* Company receives final FDA confirmation to initiate phase 3 studies using next generation i**pulse device
http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/a2.img (http://da.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/ach.img (http://adchoice.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/ach.htm)http://pi.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/a2t.imghttp://pi2.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e67fc7b/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=7lav_5yg9sU:v7SnVp_rCP4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=7lav_5yg9sU:v7SnVp_rCP4:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=7lav_5yg9sU:v7SnVp_rCP4:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=7lav_5yg9sU:v7SnVp_rCP4:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=7lav_5yg9sU:v7SnVp_rCP4:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/7lav_5yg9sU
* Company receives final FDA confirmation to initiate phase 3 studies using next generation i**pulse device
http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/a2.img (http://da.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/ach.img (http://adchoice.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/ach.htm)http://pi.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/a2t.imghttp://pi2.feedsportal.com/r/247395420095/u/49/f/654213/c/35217/s/4e67fc7b/sc/28/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e67fc7b/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=7lav_5yg9sU:v7SnVp_rCP4:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=7lav_5yg9sU:v7SnVp_rCP4:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=7lav_5yg9sU:v7SnVp_rCP4:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=7lav_5yg9sU:v7SnVp_rCP4:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=7lav_5yg9sU:v7SnVp_rCP4:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/7lav_5yg9sU